Artrya

Company profile

About Artrya

Artrya is an AI-driven healthcare company focused on transforming cardiovascular care through advanced diagnostic technology. The company partners with clinics and emergency departments to deliver new models of care for patients presenting with chest pain. Artrya's flagship product, Salix, uses artificial intelligence to analyze coronary computed tomography angiography (CCTA) scans, providing rapid insights into the type and volume of arterial plaque to facilitate accurate risk stratification of coronary artery disease patients within minutes. The company's mission centers on preventing the 600,000 American lives lost annually to undiagnosed coronary disease. Artrya's technology enables physicians to make evidence-based decisions about patient discharge, admission, and treatment pathways, moving away from the costly "just to be sure" approach that leads to over-testing. The AI-supported analysis helps quickly identify patients with minimal coronary artery disease who can be safely discharged, while catching early warning signs in at-risk patients who warrant further investigation. Artrya's solution addresses significant healthcare system inefficiencies, including the $10-13 billion spent annually on over-testing chest pain patients and the unnecessary admission of up to 90% of chest pain patients to emergency departments. The company is publicly listed on the Australian Securities Exchange and has received regulatory clearances in Australia and the United States. Artrya is headquartered in West Perth, Australia, and serves health systems, emergency departments, and primary care providers focused on improving cardiovascular care delivery and patient outcomes.

Company description · Artrya official website